The main aim of this study is to check the effectiveness and safety of maribavir for the treatment of CMV infection after HSCT in Chinese patients in real-world settings.

The participants will be treated with maribavir for up to 8 weeks.

Inclusion Criteria:

• Hematopoietic Stem Cell Transplant Recipients

  1. Adult patients with an expected survival of ≥4 weeks.
  2. Confirmed CMV infection, including CMV viremia and CMV disease.
  3. Fully understand the content of the trial, voluntarily participate and complete the trial, and voluntarily sign the informed consent form.

Exclusion Criteria:

• Participants who meet any of the following criteria are not eligible for this study:

  1. Patients currently participating in other CMV-related clinical studies, such as those receiving anti-CMV drug treatment or involved in CMV vaccine clinical studies.
  2. At screening, liver function tests show: AST > 5×ULN, or ALT > 5×ULN, or total bilirubin ≥ 3.0×ULN.
  3. Patients with psychiatric disorders or severe psychological conditions that may affect the ability to provide informed consent or participate in follow-up consultations.
  4. Participants deemed unsuitable for inclusion by the investigator.

Confirmed CMV infection, including CMV viremia and CMV disease after Hematopoietic Stem Cell Transplant.